Advanced search
Publication Cover
Clinical Lipidology Volume 7, 2012 - Issue 4
Submit an article Journal homepage
432
Views
1
CrossRef citations to date
0
Altmetric
Reviews

Lipid parameters and venous thromboembolism: clinical evidence, pathophysiology and therapeutic implications

Aurélien DellucUniversité de Bretagne Occidentale, EA 3878, Brest, F-29609 France, CHRU Brest, Département de Médecine Interne et Pneumologie, Brest, F-29609France
,
Cécile TromeurUniversité de Bretagne Occidentale, EA 3878, Brest, F-29609 France, CHRU Brest, Département de Médecine Interne et Pneumologie, Brest, F-29609France
,
Dominique MottierUniversité de Bretagne Occidentale, EA 3878, Brest, F-29609 France, CHRU Brest, Département de Médecine Interne et Pneumologie, Brest, F-29609France;INSERM, CIC 0502, Hôpital de la Cavale Blanche, Bd Tanguy Prigent, F-29609 Brest Cedex, France
&
Karine LacutUniversité de Bretagne Occidentale, EA 3878, Brest, F-29609 France, CHRU Brest, Département de Médecine Interne et Pneumologie, Brest, F-29609France;INSERM, CIC 0502, Hôpital de la Cavale Blanche, Bd Tanguy Prigent, F-29609 Brest Cedex, FranceCorrespondence[email protected]
Pages 455-469 | Published online: 18 Jan 2017
 
Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days

Abstract

Lipid parameters disorders are clearly associated with cardiovascular diseases and are one of the most important targets for primary and secondary prevention. The association between lipid parameters and venous thromboembolism (VTE) has been evaluated in several clinical studies. In this review, we present the results from available literature on lipid parameters (lipids, lipoproteins and apoproteins) and VTE, and comment on the studies’ limitations. We also describe the possible pathophysiological links between dyslipidemia and hemostasis. Then, we discuss the potential role of lipid-lowering drugs, statins and fibrates on VTE risk and the potential underlying mechanisms.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related Research Data

Activation of coagulation factor VII during alimentary lipemia.
Source: Ovid Technologies (Wolters Kluwer Health)
Risk Factors and Short-term Mortality of Venous Thromboembolism Diagnosed in the Primary Care Setting in the United Kingdom
Source: American Medical Association (AMA)
Plasma Lipoproteins, Hemostasis and Thrombosis
Source: Georg Thieme Verlag KG
High-density lipoprotein cholesterol and venous thromboembolism in the Longitudinal Investigation of Thromboembolism Etiology (LITE).
Source: American Society of Hematology
Use of statins and the subsequent development of deep vein thrombosis.
Source: American Medical Association (AMA)
Levels of Factor VIIc Associated With Decreased Tissue Factor Pathway Inhibitor and Increased Plasminogen Activator Inhibitor-1 in Dyslipidemias
Source: Ovid Technologies (Wolters Kluwer Health)
Association between rheology and components of lipoproteins in human blood. Results from the MONICA project.
Source: Ovid Technologies (Wolters Kluwer Health)
Lipids and Venous Thrombosis
Source: Wiley
Association of idiopathic venous thromboembolism with single point-mutation at Arg506 of factor V
Source: Elsevier BV
Haemostasis
Source: Elsevier BV
Binding of prothrombin to chyle chylomicrons: Effects of temperature and calcium ions, and role of surface phospholipids
Source: Elsevier BV
Early antithrombotic and anti-inflammatory effects of simvastatin versus fenofibrate in patients with hypercholesterolemia.
Source: Georg Thieme Verlag KG
Lipid parameters, lipid lowering drugs and the risk of venous thromboembolism
Source: Elsevier BV
Lipoprotein Management in Patients With Cardiometabolic Risk: Consensus Conference Report From the American Diabetes Association and the American College of Cardiology Foundation
Source: Elsevier BV
The Longitudinal Investigation of Thromboembolism Etiology
Source: American Medical Association (AMA)
HYPERCHOLESTEROLEMIA AS A RISK FACTOR FOR DEEP-VEIN THROMBOSIS
Source: Elsevier BV
A Randomized Trial of Rosuvastatin in the Prevention of Venous Thromboembolism
Source: Massachusetts Medical Society
Tissue-factor pathway inhibitor and lipoproteins : evidence for association with and regulation by LDL in human plasma
Source: Ovid Technologies (Wolters Kluwer Health)
Gemfibrozil reduces plasma prothrombin fragment F1 + 2 concentration, a marker of coagulability, in patients with coronary heart disease.
Source: Georg Thieme Verlag KG
Plasma fibrinogen and ischemic heart disease risk factors.
Source: Ovid Technologies (Wolters Kluwer Health)
Secretion of plasminogen activator inhibitor-1 from cultured human umbilical vein endothelial cells is induced by very low density lipoprotein.
Source: Ovid Technologies (Wolters Kluwer Health)
Plasma Lipoproteins Support Prothrombinase and Other Procoagulant Enzymatic Complexes
Source: Ovid Technologies (Wolters Kluwer Health)
A Novel Mechanism of Protection Against Atherothrombosis
Source: Ovid Technologies (Wolters Kluwer Health)
Lipid-lowering drugs and homocysteine.
Source: HAL CCSD
Cardiovascular Diseases and the Risk of Venous Thromboembolism: A Hospital-based Case-control Study
Source: Elsevier. Published by Elsevier B.V.
Factor VII coagulant activity is strongly associated with the plasma concentration of large lipoprotein particles in middle-aged men
Source: Elsevier BV
Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction
Source: Massachusetts Medical Society
The metabolic syndrome and the risk of venous thrombosis: a case-control study.
Source: Wiley
Lipoproteins inhibit the secretion of tissue plasminogen activator from human endothelial cells.
Source: Ovid Technologies (Wolters Kluwer Health)
High-density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C
Source: American Society for Clinical Investigation
Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBP Study Group. Groupe d'Etude de la Thrombose de Bretagne Occidentale.
Source: Georg Thieme Verlag KG
Lipid-lowering drugs and homocysteine.
Source: HAL CCSD
Hypertriglyceridemia and regulation of fibrinolytic activity.
Source: Ovid Technologies (Wolters Kluwer Health)
Vitamin K-dependent proteins bind to very low-density lipoproteins.
Source: Georg Thieme Verlag KG
Relationship of tissue factor pathway inhibitor activity to plasma lipoproteins and myocardial infarction at a young age.
Source: Georg Thieme Verlag KG
Lipoprotein Lp(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: results from the prospective Göttingen Risk Incidence and Prevalence Study (GRIPS)
Source: Wiley
Gemfibrozil reduces thrombin generation in patients with combined hyperlipidaemia, without influencing plasma fibrinogen, fibrin gel structure or coagulation factor VII.
Source: Georg Thieme Verlag KG
EPIDEMIOLOGY OF COAGULATION FACTORS, INHIBITORS AND ACTIVATION MARKERS: THE THIRD GLASGOW MONICA SURVEY II. RELATIONSHIPS TO CARDIOVASCULAR RISK FACTORS AND PREVALENT CARDIOVASCULAR DISEASE
Source: Wiley
Circulation : Clinical Summaries
Source: Ovid Technologies (Wolters Kluwer Health)
Activated protein C resistance caused by Arg506Gln mutation in factor Va
Source: Elsevier BV
Coagulation Factors, Inflammation Markers, and Venous Thromboembolism: The Longitudinal Investigation of Thromboembolism Etiology (LITE)
Source: Elsevier BV
Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment.
Source: Elsevier BV
Relationships of plasma viscosity, coagulation and fibrinolysis to coronary risk factors and angina.
Source: Georg Thieme Verlag KG
Statins and venous thromboembolism
Source: Wiley
Plasma Lipoproteins Enhance Tissue Factor–Independent Factor VII Activation
Source: Ovid Technologies (Wolters Kluwer Health)
Correlation of vitamin K-dependent clotting factors with cholesterol and triglycerides in healthy young adults.
Source: Ovid Technologies (Wolters Kluwer Health)
Circulation : Clinical Summaries
Source: Ovid Technologies (Wolters Kluwer Health)
High-Density Lipoprotein and the Risk of Recurrent Venous Thromboembolism
Source: Ovid Technologies (Wolters Kluwer Health)
Association between coagulation factors VII and X with triglyceride rich lipoproteins.
Source: BMJ
Increased Plasma Levels of Lipoprotein(a) and the Risk of Idiopathic and Recurrent Venous Thromboembolism
Source: Elsevier BV
HMG CoA reductase inhibitors and the risk of venous thrombosis among postmenopausal women.
Source: Wiley
Why should statins prevent venous thromboembolism? A systematic literature search and a call for action.
Source: Wiley
The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy--a review of the evidence.
Source: Wiley
Serum lipoprotein (a) levels in patients with first unprovoked venous thromboembolism is not associated with subsequent risk of recurrent VTE.
Source: Elsevier BV
Methylenetetrahydrofolate reductase polymorphism (C677T), hyperhomocysteinemia, and risk of ischemic cardiovascular disease and venous thromboembolism: prospective and case-control studies from the Copenhagen City Heart Study.
Source: American Society of Hematology
Statins and VTE prevention
Source: Hindawi Limited
D-dimer levels and risk of recurrent venous thromboembolism
Source: American Medical Association (AMA)
High lipoprotein(a) levels with predominance of high molecular weight apo(a) isoforms in patients with pulmonary embolism
Source: Elsevier BV
The Atherosclerosis Risk in Communities (ARIC) Study
Source: Ovid Technologies (Wolters Kluwer Health)
Relationship between venous thromboembolism and lipid or lipoprotein disorders.
Source: Elsevier BV
FIELDS OF DREAMS, FIELDS OF TEARS
Source: Hindawi Limited
Circulation : Clinical Summaries
Source: Ovid Technologies (Wolters Kluwer Health)
Circulation : Clinical Summaries
Source: Ovid Technologies (Wolters Kluwer Health)
Circulation : Clinical Summaries
Source: Ovid Technologies (Wolters Kluwer Health)

Linking provided by 

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.